| Abstract | A case of visceral leishmaniasis unresponsive to several course of treatment with standard drugs, was successfully cured by a 21 day course (50 mg/day) of liposomal amphotericin B (AmBisome, Vestar Inc.). The efficacy of the AmBisome formulation is supported by experimental studies on Leishmania donovani infected BALB/c mice where ED50 values of AmBisome and conventional amphotericin B were 0.15-0.25 and 0.95-4.9 mg/kg, respectively. A lack of toxicity of the AmBisome formulation was noted in both studies. |
| Authors | S L Croft, R N Davidson, E A Thornton
(Affiliation: Department of Medical Parasitology, London School of Hygiene and Tropical Medicine, UK.)
|
| Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 28 Suppl B
Pg. 111-8
(Oct 1991)
ISSN: 0305-7453 ENGLAND |
| PMID | 1778888
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Drug Carriers
- Liposomes
- liposomal amphotericin B
- Amphotericin B
|
| Topics |
- Adult
- Amphotericin B
(pharmacology, therapeutic use)
- Animals
- Cricetinae
- Drug Carriers
- Humans
- Leishmania donovani
(drug effects)
- Leishmaniasis, Visceral
(drug therapy, parasitology)
- Liposomes
- Macrophages
(parasitology)
- Male
- Mesocricetus
- Mice
- Mice, Inbred BALB C
- Mice, Inbred ICR
|
